ATE366731T1 - Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes - Google Patents

Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes

Info

Publication number
ATE366731T1
ATE366731T1 AT05291066T AT05291066T ATE366731T1 AT E366731 T1 ATE366731 T1 AT E366731T1 AT 05291066 T AT05291066 T AT 05291066T AT 05291066 T AT05291066 T AT 05291066T AT E366731 T1 ATE366731 T1 AT E366731T1
Authority
AT
Austria
Prior art keywords
hyperglycemia
pyrrolidine
diabetes
preparation
treatment
Prior art date
Application number
AT05291066T
Other languages
English (en)
Inventor
Nanteuil Guillaume De
Alain Benoist
Murielle Combettes
Elizabeth Harley
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of ATE366731T1 publication Critical patent/ATE366731T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05291066T 2004-05-19 2005-05-18 Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes ATE366731T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0405454A FR2870538B1 (fr) 2004-05-19 2004-05-19 Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ATE366731T1 true ATE366731T1 (de) 2007-08-15

Family

ID=34942306

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05291066T ATE366731T1 (de) 2004-05-19 2005-05-18 Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes

Country Status (29)

Country Link
US (1) US7439263B2 (de)
EP (1) EP1598350B1 (de)
JP (1) JP4335171B2 (de)
KR (1) KR100747967B1 (de)
CN (1) CN100381438C (de)
AR (1) AR049278A1 (de)
AT (1) ATE366731T1 (de)
AU (1) AU2005202180B2 (de)
BR (1) BRPI0501769A (de)
CA (1) CA2506491C (de)
CY (1) CY1106878T1 (de)
DE (1) DE602005001576T2 (de)
DK (1) DK1598350T3 (de)
EA (1) EA009292B1 (de)
ES (1) ES2290864T3 (de)
FR (1) FR2870538B1 (de)
GE (1) GEP20074103B (de)
HK (1) HK1086259A1 (de)
HR (1) HRP20070376T3 (de)
MX (1) MXPA05005256A (de)
MY (1) MY139481A (de)
NO (1) NO330294B1 (de)
NZ (1) NZ540108A (de)
PL (1) PL1598350T3 (de)
PT (1) PT1598350E (de)
RS (1) RS50526B (de)
SG (1) SG117551A1 (de)
SI (1) SI1598350T1 (de)
ZA (1) ZA200504050B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2020413A1 (de) * 2007-08-02 2009-02-04 Bayer CropScience AG Oxaspirocyclische-spiro-substituierte Tetram- und Tetronsäure-Derivate
WO2009037719A1 (en) * 2007-09-21 2009-03-26 Lupin Limited Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
JP5438028B2 (ja) * 2008-01-23 2014-03-12 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼｉｖの阻害剤としての用途
GB2483614B (en) 2009-06-18 2014-12-03 Lupin Ltd 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
US8440710B2 (en) * 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2014000629A1 (zh) * 2012-06-25 2014-01-03 广东东阳光药业有限公司 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用
KR102449196B1 (ko) 2016-01-15 2022-09-29 삼성전자주식회사 비휘발성 메모리 장치 및 비휘발성 메모리 장치의 프로그램 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0618957B2 (ja) * 1988-01-26 1994-03-16 日本合成化学工業株式会社 成形物の製造方法
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
DE4222459C2 (de) * 1992-07-08 1995-09-14 Sigma Tau Ind Farmaceuti 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
ES2167371T3 (es) * 1993-07-02 2002-05-16 Bayer Ag Derivados de 1h-3-aril-pirrolidin-2,4-diona espirociclicos substituidos.
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) * 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
DK1308439T3 (da) * 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
AU8811401A (en) * 2000-09-25 2002-04-02 Toray Industries Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
FR2824825B1 (fr) * 2001-05-15 2005-05-06 Servier Lab Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003057144A2 (en) * 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AU2003214534B2 (en) * 2002-04-08 2006-08-31 Torrent Pharmaceuticals Ltd. Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
US7262207B2 (en) * 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
PL376822A1 (pl) * 2002-11-07 2006-01-09 Merck & Co., Inc. Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy

Also Published As

Publication number Publication date
CN100381438C (zh) 2008-04-16
EP1598350A1 (de) 2005-11-23
JP2005350456A (ja) 2005-12-22
PL1598350T3 (pl) 2007-10-31
BRPI0501769A (pt) 2006-01-10
HK1086259A1 (en) 2006-09-15
NO20052414L (no) 2005-11-21
AU2005202180A1 (en) 2005-12-08
KR20060048007A (ko) 2006-05-18
US20050261501A1 (en) 2005-11-24
US7439263B2 (en) 2008-10-21
SG117551A1 (en) 2005-12-29
RS50526B (sr) 2010-05-07
EA009292B1 (ru) 2007-12-28
GEP20074103B (en) 2007-05-10
AR049278A1 (es) 2006-07-12
EP1598350B1 (de) 2007-07-11
CY1106878T1 (el) 2012-09-26
DK1598350T3 (da) 2007-11-12
NO330294B1 (no) 2011-03-21
KR100747967B1 (ko) 2007-08-08
PT1598350E (pt) 2007-10-04
ZA200504050B (en) 2006-07-26
SI1598350T1 (sl) 2007-10-31
CA2506491A1 (fr) 2005-11-19
DE602005001576T2 (de) 2008-04-17
ES2290864T3 (es) 2008-02-16
CA2506491C (fr) 2009-09-01
NO20052414D0 (no) 2005-05-19
FR2870538A1 (fr) 2005-11-25
DE602005001576D1 (de) 2007-08-23
HRP20070376T3 (en) 2007-12-31
NZ540108A (en) 2006-04-28
AU2005202180B2 (en) 2010-10-28
MY139481A (en) 2009-10-30
MXPA05005256A (es) 2005-11-24
FR2870538B1 (fr) 2006-07-14
EA200500683A1 (ru) 2005-12-29
CN1721417A (zh) 2006-01-18
JP4335171B2 (ja) 2009-09-30

Similar Documents

Publication Publication Date Title
ATE395342T1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE602005002470D1 (de) 1-aminophthalazinderivate, deren herstellung und deren therapeutische verwendung
ATE366731T1 (de) Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes
DE602007005487D1 (de) Harnstoffderivate von tropan, ihre herstellung und ihre therapeutische anwendung
ATE447570T1 (de) Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen
DE602007004119D1 (de) N-(aminoheteroaryl)-1h-indol-2-carboxamid-derivate sowie deren herstellung und therapeutische anwendung
DE602005015841D1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
DE502005006424D1 (de) Neue alkyl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
DE602005021501D1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
DE602005027546D1 (de) Aryl- und heteroarylpiperidincarboxylatderivate, deren herstellung und deren verwendung in form von faah-enzyminhibitoren
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
ATE502006T1 (de) Alkyl-, alkenyl- und alkynylcarbamat-derivate, deren herstellung und therapeutische verwendung
DE602005011450D1 (de) N-(1 h-indolyl)-1 h- indol-2-carboxamid-derivate, deren herstellung und therapeutische verwendung damit
DE502007005708D1 (de) 3 -amino- imidazo ä1,2-aüpyridinderivate mit sglt1 und sglt2 hemmender wirkung zur behandlung von diabetes vom typ 1 und typ 2
ATE504595T1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE602006005246D1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
DE602004017463D1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
ATE417846T1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
DE60305037D1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
DE602006005640D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit
DE602006015675D1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
DE602004003751D1 (de) Heterocyclische Oximderivate, Verfahren zu ihrer Herstellung und Verwendung in der Behandlung von Typ II Diabetes
ATE499351T1 (de) Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung